Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

25.15
-0.1200-0.47%
Post-market: 25.160.0050+0.02%17:43 EST
Volume:43.79M
Turnover:1.10B
Market Cap:143.00B
PE:14.57
High:25.32
Open:25.32
Low:25.04
Close:25.27
52wk High:27.69
52wk Low:20.92
Shares:5.69B
Float Shares:5.68B
Volume Ratio:1.04
T/O Rate:0.77%
Dividend:1.70
Dividend Rate:6.76%
EPS(TTM):1.73
EPS(LYR):1.42
ROE:10.60%
ROA:5.19%
PB:1.54
PE(LYR):17.74

Loading ...

Pfizer Price Target Announced at $26.00/Share by Citigroup

Dow Jones
·
Yesterday

Valuation Soars 25x! This Biotech Bets on IPO with Pfizer and Novo Nordisk's Coveted cAMP Tech

Deep News
·
Yesterday

Pfizer : Citigroup Resumes Coverage With Neutral Rating; Target Price $26

THOMSON REUTERS
·
Yesterday

U.S., U.K. Strike Deal on Higher Drug Prices -- WSJ

Dow Jones
·
Yesterday

EMA Validates Pfizer and Astellas Type II Variation Application for PADCEV and KEYTRUDA in Muscle-Invasive Bladder Cancer

Reuters
·
Yesterday

Pfizer Inc. to Provide Full-Year 2026 Financial Guidance in Analyst Webcast

Reuters
·
Dec 01

FDA's Prasad Cites Alleged Child COVID Shot Deaths in Push for Stricter Rules

Benzinga_recent_news
·
Nov 30

Pfizer (PFE) Gets a Hold from Wells Fargo

TIPRANKS
·
Nov 28

Pantera Minerals Limited Announces Name Change Reflecting Broader Focus

TIPRANKS
·
Nov 27

Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)

TIPRANKS
·
Nov 26

Valneva Se - Pfizer Aims to Submit a Biologics License Application to U.S. FDA and Marketing Authorization Application (Maa) to European Medicines Agency in 2026

THOMSON REUTERS
·
Nov 26

Patent Challenges Cloud Hithium's IPO Prospects as Legal and Financial Risks Mount

Deep News
·
Nov 26

Should FDA Approval of PADCEV Plus Keytruda Shift Pfizer's (PFE) Oncology Innovation Outlook?

Simply Wall St.
·
Nov 25

NYSE Most Active Issues

Dow Jones
·
Nov 25

Pfizer Is Maintained at Buy by Guggenheim

Dow Jones
·
Nov 24

Guggenheim Adjusts Price Target on Pfizer to $35 From $33, Maintains Buy Rating

MT Newswires Live
·
Nov 24

A Look at Pfizer's Valuation Following FDA Approval of PADCEV Combination Therapy for Bladder Cancer

Simply Wall St.
·
Nov 23

First-Ever Human H5N5 Case Turns Fatal In Washington State

Benzinga
·
Nov 23

Pfizer Completes $5 Billion Public Offering

TIPRANKS
·
Nov 22

Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Nov 22